The Motley Fool takes a closer look Covance's earnings and free cash flow

First-quarter financial results for Covance ($CVD) were a mixed bag that showed growth in one field (late-stage development), and decline in others (early-stage development and toxicology). But while the CRO posted overall revenue growth, Seth Jayson from The Motley Fool asks investors to take a closer look at Covance's free cash flow. "An increase in cash flow based on stiffing your suppliers (by increasing accounts payable for the short term) or shortchanging Uncle Sam on taxes will come back to bite investors later," the article says. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

PRA Health has hired a former FDA clinical research lead to help run its decentralized study unit.